Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 14, 2016, reports on a material definitive agreement entered into on July 12, 2016. Evolent Health, Inc. (the "Company") has agreed to acquire Valence Health, Inc. ("Valence") through a merger with a wholly-owned subsidiary, Electra Merger Sub, LLC. The transaction is expected to close within 120 days, subject to regulatory approvals and other customary conditions.
Key Financial Metrics and Transaction Structure
The filing details the financial structure of the proposed acquisition rather than the Company's operational financial results for a specific period.
- Total Merger Consideration: Approximately $142.8 million to $144.1 million, based on the Company's stock price on July 12, 2016.
- Share Consideration: 5.29 million to 5.84 million shares of the Company's Class A common stock.
- Cash Consideration: Approximately $35 million to $44 million.
- Contingent Earn-Out: Up to $50 million in additional shares, payable if Valence achieves specific new business activity targets for the remainder of 2016 impacting 2017 results.
- Escrow: $11.4 million of the Share Consideration will be held in escrow for 15 months to secure indemnification obligations.
- Exclusions: The acquisition excludes Valence's contracts serving state insurance cooperatives, which will be transferred to a separate entity owned by current Valence stockholders.
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes and Conditions
The primary material change is the execution of the Merger Agreement. The transaction is subject to several closing conditions, including:
- Approval by Valence's stockholders.
- Receipt of specified consents and regulatory approvals.
- Expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Accuracy of representations and warranties and compliance with covenants by both parties.
- Absence of legal impediments to the consummation of the Merger.
The Merger is not subject to any financing condition. Post-closing adjustments to the aggregate consideration may occur based on working capital, indebtedness, liabilities, and transaction expenses.
Guidance, Risks, and Unusual Items
The Company issued a press release on July 13, 2016, regarding the transaction. The filing includes standard forward-looking statements disclaiming obligations to update such statements. Key risks identified include:
- Delays in or failure of the Merger to close.
- Litigation or other matters affecting the closing.
- Failure to achieve the earn-out conditions for the additional $50 million consideration.
The issuance of shares to Valence stockholders is exempt from registration under Section 4(a)(2) of the Securities Act as it involves only "accredited investors" and does not constitute a public offering.
Investor Verification Checklist
- Verify the final closing date and whether all regulatory approvals (including HSR Act) have been obtained.
- Confirm the final share count and cash amount paid, noting potential adjustments for working capital and debt.
- Monitor the performance of Valence's new business activity to determine if the $50 million earn-out is triggered.
- Review the status of the $11.4 million escrow account and any claims filed against it after the 15-month release period.
- Assess the impact of excluding state insurance cooperative contracts on the overall value of the acquired business.